Tirzepatide
A prescription medicine that works on two gut-hormone receptors instead of one, both tied to appetite and blood sugar.
Learn about TirzepatideA prescription medicine that copies a gut hormone released after meals, so you feel full sooner and stay full longer.
Semaglutide copies GLP-1, a hormone your gut releases after you eat. It is sold under the names Ozempic, Wegovy, and Rybelsus, and it is given as a weekly shot or a daily pill depending on the product.
It calls for an evaluation and ongoing care from a provider as part of a whole-person weight plan.
GLP-1 medicines started as diabetes treatments. Doctors noticed that people taking them also lost weight, and later trials were built around that finding.
It is now one of the most widely used medicines of its kind. Depending on the product, its approvals cover type 2 diabetes and long-term weight management.
It is not the only option. Tirzepatide reaches a second receptor, and other medicines in the group work in similar ways, so the choice is a clinical one.
GLP-1 is a hormone your small intestine releases after a meal. It tells your brain you have eaten, slows how fast the stomach empties, and helps the pancreas release insulin at the right moment.
Semaglutide is built to look like GLP-1, so it turns on the same receptors. The difference is that it lasts for days rather than minutes, so the fullness signal keeps working between meals.
The practical result is that you feel full sooner, stay full longer, and think about food less often. Blood sugar tends to steady out for the same reason.
It works alongside food and activity changes, not instead of them. Most programs pair the medicine with nutrition support and regular check-ins.
Adults who have worked at diet and exercise without lasting results and want a medical path
People with weight-related health concerns who want to talk options through with a clinician
Individuals weighing semaglutide against tirzepatide after reading about both
Adults who want regular follow-up rather than a prescription and no further contact
How this therapy compares to related options—not a recommendation.
Reaches the GIP receptor as well as GLP-1, so it acts on two pathways instead of one. Both are FDA-approved, and which fits you is a provider's decision.
For therapies that require medical evaluation, every protocol is designed by a licensed provider.
Suitability for Semaglutide is determined by a licensed provider after evaluation.
Other compounds that support overlapping wellness goals.
Semaglutide is FDA-approved as a prescription medicine for certain uses. A licensed provider decides after an evaluation whether it is a good fit for you.
Therapies that require medical evaluation are sourced from FDA-regulated 503A compounding pharmacies.
For therapies that require medical evaluation, every protocol is designed by a licensed provider.
Semaglutide is FDA-approved, but only for specific uses. Your provider decides whether one of them applies to you.
Nausea, and sometimes vomiting or constipation, are the most common side effects, especially in the first weeks.
It carries a boxed warning about a thyroid tumor seen in rats. Your provider will ask whether you or a close relative has had medullary thyroid cancer.
Results differ from person to person, and nothing here promises an outcome.
See current pricing and availability for Semaglutide in our shop. If a medical evaluation is needed, a licensed provider guides you through it.
Individual results vary. General information on this site is not a substitute for professional medical advice.